Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy.

Name: Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy.
Author: Bohr, Adam

Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy. — المؤلف: Bohr, Adam — Molecules (Basel, Switzerland) 20190401

المؤلف: Bohr, Adam
النشر: Molecules (Basel, Switzerland) 20190401
الموضوعات: Administration, Oral؛ Anilides؛ Animals؛ Biological Availability؛ Docetaxel؛ Drug Stability؛ Drug Synergism؛ Humans